A deep conversation accounting for a patient’s medical characteristics and their goals for treatment dictates which tyrosine kinase inhibitor (TKI) Jo...

Ruxolitinib has been used as a therapy for myelofibrosis for approximately 15 years, as of 2025. According to Francesca Palandri, MD, PhD, it has demo...

Subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) significantly reduced the risk of disease progression or death compared with active...

As multiple myeloma treatment has evolved throughout the years, oncologists are now closer than ever to saying they have a “cure” for the disease, not...

The addition of benmelstobart (TQB2450) to anlotinib (Fukewei) exhibited advantageous progression-free survival (PFS) outcomes vs sunitinib (Sutent) i...

Mosunetuzumab-axgb (Lunsumio) displayed clinically meaningful and durable responses among a dedicated cohort of patients with previously untreated mar...

According to Jorge Cortes, MD, director, and Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer of the Georgia Cancer Center, outcomes with hi...

In the management of ccRCC following progression on first-line therapy, second-line treatment decisions are increasingly influenced by the initial reg...

In an interview with CancerNetwork® on nutrition during cancer treatment, Denise B. Reynolds, RD, discussed whether she observes deficiencies in vitam...

This case highlights the complexity of managing a patient with intermediate-risk metastatic ccRCC following progression on a first-line IO/TKI regimen...